LifeMD (LFMD) Registration Filing summary

Company overview and business model

• Operates a direct-to-patient telehealth platform offering virtual and in-home healthcare across the U.S., integrating a 50-state medical group, pharmacy network, lab/diagnostic services, EMR, and patient care center.

• Provides primary care, men's health, weight management, sleep, hair loss, and hormonal therapy, primarily on a subscription basis.

• Focuses on expanding treatment areas and enhancing patient experience through proprietary technology and high-quality providers.

Financial performance and metrics

• As of March 31, 2024, net tangible book value was a deficit of $15.2 million, or $(0.37) per share.

• After a $53.3 million offering at $7.53/share, adjusted net tangible book value would be $36.5 million, or $0.76 per share, with immediate dilution of $6.77 per share to new investors.

• Outstanding as of March 31, 2024: 40,628,636 shares of common stock, with additional options, warrants, and convertible securities potentially dilutive.

Use of proceeds and capital allocation

• Proceeds from offerings will be used for general corporate purposes, including working capital, sales and marketing, brand expansion, R&D, and capital expenditures.

• Management retains broad discretion over allocation of funds.

• Pending use, proceeds may be held in cash or short-term investments.